

18 November 2010

## December 2010 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **December 2010** Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

### New listings

- Rivaroxaban (Xerelto) tab 10 mg, 15 tab pack (p'code 2336324) and 30 tab pack (p'code 2336316) – Special Authority – Retail pharmacy
- Gemfibrozil (Lipazil) tab 600 mg (p'code 472875)
- Menthol (Midwest) crystals, 25 g – Only in combination (p'code 2377209)
- Sulphur (Midwest) precipitated 100 g – Only in combination (p'code 2121158)
- Moxifloxacin (Avelox) tab 400 mg – Special Authority – Retail pharmacy (p'code 2022362)
- Itraconazole (Itrazole) cap 100 mg – Retail pharmacy-Specialist (p'code 2354322)
- Escitalopram (Loxalate) tab 10 mg (p'code 2347792) and 20 mg (p'code 2347806)
- Sertraline (Arrow-Sertraline) tab 50 mg (p'code 2376520) and 100 mg (p'code 2376539)
- Glycerin with sucrose (Ora-Sweet) suspension – Only in combination with Ora-Plus (p'code 2377241)
- Glycerin with sodium saccharin (Ora-Sweet SF) – Only in combination with Ora-Plus (p'code 2377268)
- Methyl hydroxybenzoate (Midwest) powder, 25 g (p'code 2018853)
- Methylcellulose with glycerin and sucrose (Ora-Blend) suspension – Only in combination (p'code 2377217)
- Methylcellulose with glycerin and sodium saccharin (Ora-Blend SF) suspension – Only in combination (p'code 2377225)
- Methylcellulose (Ora-Plus) suspension – Only in combination (p'code 2377233)
- Propylene glycol (Midwest) liq, 500 ml – Only in extemporaneously compounded methyl hydroxybenzoate 10% solution. (p'code 2177447)
- Sodium bicarbonate (Midwest) powder BP, 500 g – Only in extemporaneously compounded omeprazole suspension (p'code 2032880)

### Changes to restrictions

- Levomepromazine – chemical name change from methotrimeprazine
- Multiple Sclerosis Treatments – amended stopping criteria
- Temozolomide (Temodal) cap 5 mg, 20 mg, 100 mg and 250 mg – amended Special Authority criteria

### Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Loperamide hydrochloride	Tab 2 mg	Nodia	
Cilazapril	Tab 0.5 mg, 2.5 mg and 5 mg	Zapril	Inhibace
Labetalol	Tab 50 mg, 100 mg and 200 mg	Hybloc	
Propranolol	Cap long-acting 160 mg	Cardinol LA	
Nifedipine	Tab long-acting 30 mg and 60 mg	Adefin XL	
Isosorbide mononitrate	Tab long-acting 60 mg	Duride	
Menthol	Crystals, 25 g	PSM Midwest	
Amoxicillin	Cap 250 mg and 500 mg	Alphamox	Apo-Amoxi

Naproxen sodium	Tab 275 mg Tab 550 mg	Sonaflam Synflex	
Interferon beta-1-beta	Inj 8 million iu per 1 ml	Betaferon	
Carboplatin	Inj 10 mg per ml, 45 ml and 100 ml	Carboplatin Ebewe	
Oxaliplatin	Inj 50 mg and 100 mg Inj 1 mg for ECP	Oxaliplatin Ebewe Baxter	
Calcium folinate	Inj 1 g	Calcium Folate Ebewe	
Methotrexate	Inj 100 mg per ml, 10 ml and 50 ml Inj 1 mg for ECP	Methotrexate Ebewe Baxter	
Doxorubicin	Inj 100 mg and 200 mg	Doxorubicin Ebewe	
Epirubicin	Inj 2 mg per ml, 50 ml and 50 ml Inj 1 mg for ECP	Epirubicin Ebewe Baxter	
Paclitaxel	Inj 30 mg, 100 mg, 150 mg, 300 mg and 600 mg Inj 1 mg for ECP	Paclitaxel Ebewe Baxter	
Chloramphenicol	Eye drops 0.5%	Chlorafast	Chlorsig
Methyl hydroxybenzoate	Powder, 25 g	ABM Midwest PSM	
Propylene glycol	Liq, 500 ml	ABM Midwest PSM	

#### Increased Subsidy

Chemical	Presentation	Fully subsidised brands
Chlorhexidine gluconate	Mouthwash 0.2%, 200 ml OP	Rivacol
Doxorubicin	Inj 10 mg and 50 mg Inj 1 mg for ECP	Doxorubicin Ebewe Baxter

**NB.** For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: [www.pharmac.govt.nz/healthpros/Schedule](http://www.pharmac.govt.nz/healthpros/Schedule).

#### Varenicline (Champix) Special Authority clarification

Champix tablets were listed fully subsidised as a smoking cessation treatment, subject to Special Authority criteria, from 1 November 2010. One of the Special Authority criteria refers to patients not having used varenicline in the last 12 months (criterion 4). We would like to clarify that this means patients must not have used **subsidised** varenicline in the last 12 months. This criterion has already been amended on the Special Authority form.

**New CFC-free Salbutamol with Ipratropium Bromide Aerosol Inhaler**

A new CFC-free salbutamol with ipratropium bromide aerosol inhaler will be available early in 2011 as a replacement for Combivent. Duolin HFA from Rex Medical has gained registration by Medsafe. Duolin HFA stock will be available and fully subsidised in the market in February 2011 at the following price and subsidy:

<b>Chemical and strength</b>	<b>Presentation</b>	<b>Pack size</b>	<b>Proposed price and subsidy</b>
Salbutamol 100 µg with 20 µg ipratropium	Aerosol inhaler, CFC-free	200 doses OP	\$12.19

Combivent will continue to be listed at the current price and subsidy until stock is depleted, which is expected to be early in the new year